Management of cardiogenic shock due to acute coronary syndromes

Angiology

Volumn 56, Issue 2, 2005, Pages 123-130

  Bouki, Konstantina P ^a,b   Pavlakis, Georgios ^a   Papasteriadis, Evaggelos ^a  

^a General Hospital of Nikea   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; FIBRINOLYTIC AGENT; INOTROPIC AGENT; LEVOSIMENDAN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; AORTA BALLOON; CARDIOGENIC SHOCK; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEMOPERFUSION; HUMAN; HYPOTENSION; INCIDENCE; MORTALITY; PROTON SODIUM EXCHANGE; REVIEW; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

CARDIOTONIC AGENTS; CORONARY DISEASE; HUMANS; INTRA-AORTIC BALLOON PUMPING; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SHOCK, CARDIOGENIC; SURVIVAL RATE; SYNDROME; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 15544387797     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600201     Document Type: Review

References (63)

1. Goldberg RJ, Samad NA, Yarzebski J, et al: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 340:1162-1168, 1999.
2. Holmes DR, Califf RM, Van de Werf F, et al, for the GUSTO-I investigators: Difference in the countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: Results from the GUSTO trial. Lancet 349:75-78, 1997.
3. Hochman JS, Sleeper LA, Godfrey E, et al, for the SHOCK trial study group: Should we emergently revascularise occluded coronaries for cardiogenic shock: An international randomized trial of emergency PTCA/CABG trial design. Am Heart J 137:313-321, 1999.
4. Menon V, Hochman JS: Management of cardiogenic shock complicating acute myocardial infarction. Heart 88:531-537, 2002.
5. Holmes DR, Bates ER, Kleiman NS, et al: Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J Am Coll Cardiol 26:668-674, 1995.
6. Hasdai D, Harrington RA, Hochman JS, et al: Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 36:685-692, 2000.
7. Hasdai D, Holmes DR, Topol EJ, et al: Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase: Results from GUSTO III. Eur Heart J 20:128-135, 1999.
8. Holmes DR, Beger PB, Hochman JS, et al: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 100:2067-2073, 1999.
9. Lindholm MG, Kober L, Boesgaard S, et al, on behalf of the TRACE study group: Cardiogenic shock complicating acute myocardial infarction. Prognostic impact of early and late shock development. Eur Heart J 24:258-265, 2003.
10. Killip T: Cardiogenic shock complicating myocardial infarction. J Am Coll Cardiol 14:47-48, 1989.
11. Hochman JS, Buller CE, Sleeper LA, et al, for the SHOCK investigators: Cardiogenic shock complicating acute myocardial infarction. Etiologies, management and outcome: A report from the SHOCK trial registry. J Am Coll Cardiol 36:1063-1070, 2000.
12. Webb JG, Sleeper LA, Buller CE, et al, for the SHOCK investigators: Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: A report from the SHOCK trial Registry. J Am Coll Cardiol 36:1084-1090, 2000.
13. Hasdai D, Califf RM, Thompson TD, et al: Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 35:136-143, 2000.
14. Richard C, Ricome JL, Rimailho A, et al: Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 67:620-626, 1983.
15. Gage J, Rutman H, Lucido D, et al: Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74:367-373, 1986.
16. Moiseyev VS, Poder P, Andrejevs, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction (RUSSLAN). Eur Heart J 23:1422-1432, 2002.
17. Lopez-Sendon J, Gonzalez A, Lopez De Sa E, et al: Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: Sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. J Am Coll Cardiol 19:1145-1153, 1992.
18. Pretre R, Ye Q, Grunenfelder J, et al: Operative results of "repair" of ventricular septal rupture after acute myocardial infarction. Am J Cardiol 84:785-788, 1999.
19. Tanaka H, Hasegawa S, Sakamoto T, et al: Postinfarction ventricular septal perforation repair with endoventricular patch plasty using double patches and gelatin-resorcinol-formaldehyde biological glue. Eur J Cardiothorac Surg 19:945-948, 2001.
20. Labrousse L, Choukroun E, Chevalier JM, et al: Surgery for postinfarction ventricular septal defect (VSD): Risk factors for hospital death and long-term results. Eur J Cardiothorac Surg 21:725-731, 2002.
21. Hendry PJ, Masters RG, Mussivand TV, et al: Circulatory support for cardiogenic shock due to acute myocardial infarction: A Canadian experience. Can J Cardiol 15:1090-1094, 1999.
22. Magovern JA, Sussman MJ, Goldstein AH, et al: Clinical results with the AB-180 left ventricular assist device. Ann Thorac Surg 71:S121-S124, 2001.
23. Boehemer JP, Pae WP, Silber D, et al: Poor outcome with left ventricular assist devices as a bridge to transplant following myocardial infarction with cardiogenic shock (abstract). J Am Coll Cardiol 33: 208A, 1999.
24. Gacioch GM, Ellis SG, Lee L, et al: Cardiogenic shock complicating acute myocardial infarction: The use of coronary angioplasty and the integration of the new support devices into patient management. J Am Coll Cardiol 19:647-653, 1992.
25. Bengtson JR, Kaplan AJ, Pierer KS, et al: Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 20:1482-1489, 1992.
26. Noble S, Mc Tavish D: Reteplase: A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 52:589-605, 1996.
27. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico. Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet ii:397-401, 1986.
28. Prewitt RM, Gu S, Garber PJ, et al: Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 20:1626-1633, 1992.
29. Becker RC: Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: A theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J 125:919-929, 1993.
30. Mueller H, Ayres SM, Conklin EF, et al: The effects of intra-aortic counterpulsation on cardiac performance and metabolism in shock associated with acute myocardial infarction. J Clin Invest 50:1885-1900, 1971.
31. Nanas JN, Moulopoulos SD: Counterpulsation: Historical back-ground, technical improvements, hemodynamic and metabolics effects. Cardiology 84:156-167, 1994.
32. Goldberger M, Tabak SW, Shah PK: Clinical experience with intra-aortic balloon counterpulsation in 112 consecutive patients. Am Heart J 111:497-502, 1986.
33. Nanas JN, Nanas SN, Kontoyannis DA, et al: Myocardial salvage by the use of reperfusion and intraaortic balloon pump: Experimental study. Ann Thorac Surg 61:629-634, 1996.
34. Prewitt RM, Gu S, Schick U, et al: Intra-aortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol 23:794-798, 1994.
35. Sanborn TA, Sleeper LA, Bates ER, et al: Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 36(3 suppl A):1123-1129, 2000.
36. Barron HV, Every NR, Parsons LS, et al: The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2. Am Heart J 141:933-939, 2001.
37. Moosvi AR, Khaja F, Vilanueva L, et al: Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 19:907-914, 1992.
38. Hibbard MD, Holmes DRJ, Bailey KR, et al: Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 19:639-646, 1992.
39. Antoniucci D, Valenti R, Santoro GM, et al: Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: In-hospital and long-term survival. J Am Coll Cardiol 31:294-300, 1998.
40. Lindholm MG, Aldershvile J, Sundgreen C, et al: Effect of early revascularisation in cardiogenic shock complicating acute myocardial infarction. A single-center experience. Eur J Heart Fail 5:73-79, 2003.
41. Urban P, Stauffer JC, Bleed D, et al: A randomized evaluation of early revascularisation to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 20:1030-1038, 1999.
42. Webb JG, Sanborn TA, Sleeper LA, et al, for the SHOCK investigators: Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 141:964-970, 2001.
43. Hochman JS, Boland J, Sleeper LA, et al: Current spectrum of cardiogenic shock and effect of early revascularisation on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 91:873-881, 1995.
44. Edep ME, Brown DL: Effect of early revascularisation on mortality from cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 85:1185-1188, 2000.
45. Berger PB, Holmes DR, Stebbins AL, et al: Impact of an aggressive invasive catheterization and revascularisation strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries Arteries (GUSTO I) trial. An observational study. Circulation 96:122-127, 1997.
46. Berger PB, Tuttle RH, Holmes DR, et al: One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularisation. Results from GUSTO-I. Circulation 99:873-878, 1999.
47. Hochman JS, Sleeper LA, Webb JG, et al, for the SHOCK investigators. Early revascularisation in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 341:625-634, 1999.
48. Picard MH, Davidoff R, Sleeper L, et al, for the SHOCK trial: Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 107:279-288, 2003.
49. Menon V, Fincke R: Cardiogenic shock: A summary of the randomized SHOCK. Congest Heart Fail 9:35-39, 2003.
50. Shereif HR, Kloner RA: No-reflow phenomenon. Circulation 105:656-662, 2002.
51. Topol EJ, Yadav JS: Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101:570-580, 2000.
52. Williams MS, Coller BS, Vaananen HJ, et al: Activation of platelets in platelet-rich plasma by rotablation is speed dependent and can be inhibited by abciximab (c7E3 Fab; Reopro). Circulation 98:742-748, 1998.
53. Giri S, Mitchel J, Azar RR, et al: Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 89:126-131, 2002.
54. Antoniucci D, Valenti R, Migliorini A, et al: Abciximab therapy improves 1-month survival rate in unselected patients with acute myocardial infarction undergoing routine infarct artery stent implantation. Am Heart J 144:315-322, 2002.
55. Montalescot G, Barragan P, Wittenberg O, et al: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895-1903, 2001.
56. Antoniucci D, Valenti R, Migliorini A, et al: Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 90:353-357, 2002.
57. Taniyama Y, Ito H, Ivakura K, et al: Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 30:1193-1199, 1997.
58. Engler R: Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia. Fed Proc 46:2407-2412, 1987.
59. Ito H, Taniyama Y, Iwakura K, et al: Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 33:654-660, 1999.
60. Apstein CS: Glucose-insulin-potassium for acute myocardial infarction: Remarkable results from a new prospective, randomized trial [editorial] [Review]. Circulation 98:2223-2226, 1998.
61. Avkiran M: Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Am J Cardiol 83:10-17G, 1999.
62. Erhardt LR: GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes. Am J Cardiol 83:23-25G, 1999.
63. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI trial). J Am Coll Cardiol 38:1644-1650, 2001.